Table of Contents
Johnson & Johnson is one of the world’s largest healthcare companies, operating across pharmaceutical and medical technology segments following the 2023 spinoff of its consumer health division as Kenvue. Its relationship with Israel is principally that of a significant strategic foreign investor in the Israeli medical device and life sciences sector, not that of a defence contractor, surveillance technology provider, or active political advocate.
The BDS-1000 score of 434 (Tier C) is driven almost entirely by V-ECON: J&J’s approximately USD 1 billion acquisition of Israeli medical technology company Itamar Medical in 2022, its decades-long ownership and operation of Biosense Webster’s R&D and manufacturing facility in Yokneam Illit, and its operation of the JLABS @ Jerusalem life sciences incubator in formal partnership with the Jerusalem Municipality.12 These wholly-owned, directly controlled operations constitute confirmed strategic foreign direct investment in Israel with substantial capital commitment, ongoing employment, and ecosystem significance in the Israeli medtech sector.
The remaining three domains score low. No direct defence procurement relationship with Israeli military or security bodies has been identified; J&J’s medical and consumer products may reach IDF supply chains through civilian distributor channels but no affirmative evidence of a direct contract exists.3 In the digital domain, a single pre-2020 named customer case study documents J&J as a purchaser of Israeli-origin cybersecurity software (CyberArk PAM), though the continuity of this relationship post-2023 is unconfirmed; J&J has no documented role as a technology provider to Israeli state or security bodies.4 Politically, J&J has maintained an asymmetric silence on the Israel-Palestine conflict relative to its named public positions on Russia-Ukraine and racial justice — a documented double standard — but has not engaged in active lobbying, financial donations to pro-Israel parastatal organisations, or state-honour participation.5
Key uncertainties include: the completeness of Israeli Government Procurement Administration records for IDF medical supply chains; the post-Kenvue continuity of the CyberArk deployment; the current operational status of JLABS @ Tel Aviv; and the post-acquisition status of Israel Innovation Authority grants previously received by Itamar Medical.
| Date | Event |
|---|---|
| 1886 | Johnson & Johnson founded in New Brunswick, New Jersey, USA, by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson 6 |
| 1943 | Robert Wood Johnson II authors J&J’s Credo, the company’s foundational governance document 7 |
| 1998 | J&J acquires Biosense Webster, Israeli-origin electrophysiology company; R&D and manufacturing remain in Yokneam Illit, Israel 8 |
| 2018–2019 | CyberArk case study documents J&J as a customer of CyberArk’s Privileged Access Security Solution in enterprise-wide PAM deployment (pre-2020; continuity post-Kenvue unconfirmed) 4 |
| 2019 | JLABS @ Jerusalem opens in formal partnership with the Jerusalem Municipality as part of J&J Innovation’s global incubator network 12 |
| 2021 | IBM and J&J announce partnership on hybrid cloud and AI-enabled digital health 9 |
| March 2022 | J&J issues named statement suspending new business activities in Russia following Ukraine invasion; pledges continued humanitarian medicine supply to Ukraine 5 |
| March 2022 | J&J announces agreement to acquire Itamar Medical for approximately USD 1 billion 10 |
| 2022 | J&J completes acquisition of Itamar Medical (Israeli-origin cardiovascular/sleep diagnostics company); Itamar Medical becomes a wholly-owned J&J MedTech subsidiary with R&D and manufacturing operations continuing in Caesarea, Israel 1112 |
| August 2023 | J&J completes spinoff of consumer health division as Kenvue Inc. (NYSE: KVUE), retaining Innovative Medicine and MedTech segments 13 |
| October 2023– | Gaza conflict begins following Hamas attack of 7 October 2023; J&J issues no named conflict-specific public statement; general humanitarian health language only identified in corporate communications 14 |
Johnson & Johnson was founded in 1886 in New Brunswick, New Jersey, and incorporated under New Jersey law. The company’s foundational governing document is the Credo, authored in 1943, which articulates obligations to customers, employees, communities, and shareholders in that order, with no geopolitical mission or state-aligned mandate.7 J&J is publicly traded (NYSE: JNJ) with no sovereign wealth fund, state entity, or Israeli-domiciled party holding a disclosed controlling stake; its institutional shareholders are principally US-domiciled asset managers including Vanguard, BlackRock, and State Street.15
Following the August 2023 Kenvue spinoff, J&J operates across two segments: Innovative Medicine (previously Janssen Pharmaceuticals) and MedTech, which encompasses surgical technology, electrophysiology, orthopaedics, and cardiovascular and sleep diagnostics.1315 The company employs more than 130,000 people globally. Israel is not broken out as a named strategic growth market or discrete revenue geography in J&J’s public segment disclosures; Israeli operations are consolidated within the broader International or EMEA reporting segment.15
J&J’s Israeli operational footprint encompasses four documented entities: Itamar Medical (wholly-owned MedTech subsidiary, Caesarea), Biosense Webster (wholly-owned MedTech subsidiary, Yokneam Illit), JLABS @ Jerusalem (J&J Innovation incubator, Jerusalem), and Janssen Israel (commercial pharmaceutical office).1118 These operations span medical device manufacturing, R&D in cardiovascular and sleep diagnostics, life sciences incubation, and pharmaceutical commercial activity. No J&J facility has been identified in the West Bank, Gaza, or Golan Heights in public records including the Who Profits database.3
The V-MIL domain examines J&J’s relationship with Israeli defence and security procurement across six sub-categories: direct defence contracting, dual-use product variants, heavy machinery and construction, supply chain integration with defence primes, logistical sustainment, and munitions and weapons systems. Across all six categories, no affirmative public evidence of a direct relationship between J&J and Israeli military or security bodies has been identified. The domain scores at the Incidental band (I = 1.50, M = 1.50, P = 2.50), producing a V-MIL score of approximately 0.11 — the lowest of the four domains.
No direct contract, tender award, framework agreement, or memorandum of understanding between J&J and the Israeli Ministry of Defence, the Israel Defence Forces, the Israel Prison Service, or the Israel Border Police for defence equipment, weapons systems, or security infrastructure has been identified in any publicly available procurement record.316 J&J maintains an Israeli subsidiary engaged in commercial pharmaceutical and medical device sales through the standard civilian healthcare market, but this constitutes a commercial trading relationship, not a documented defence procurement relationship.
The closest the evidence comes to a plausible military supply chain connection is the possibility that J&J’s commercially ubiquitous medical consumables — Ethicon sutures and wound closure products, pharmaceutical formulations, surgical instruments — could reach IDF Medical Corps supply chains through civilian distributor channels. The Israeli Government Procurement Administration manages IDF medical supply procurement, but its records are not comprehensively published in open-source datasets, and no verified direct IDF Medical Corps contract with J&J has been identified.3 This pathway, if it exists, would represent civilian-market commodity procurement at most two steps removed from J&J — consistent with the Very Low Proximity score of 2.50.
J&J’s MedTech product portfolio — including the Ottava robotic surgery system, the MONARCH bronchoscopy platform, the Velys orthopaedic robotics system, and the DePuy Synthes trauma and spine portfolio — is purpose-designed for civilian clinical environments and is not marketed in military-specification or tactical variants.17 Ethicon products used in trauma contexts globally are standard clinical instruments available through civilian medical supply chains; no purpose-built military variant has been identified. This is the structural basis for the Impact score of 1.50 (Incidental band): J&J’s products are not designed for military application, and any military use is incidental to civilian market sales.
J&J does not manufacture heavy construction equipment, armoured vehicles, demolition machinery, or any product category associated with settlement construction or separation barrier maintenance. The machinery categories documented by NGOs and UN bodies in connection with Israeli construction activities — Caterpillar, Volvo CE, Hyundai — are entirely outside J&J’s manufacturing scope.18 This sub-category is structurally inapplicable and contributes no material risk. Similarly, J&J has no verified supply relationship with Elbit Systems, Israel Aerospace Industries, Rafael Advanced Defense Systems, or Israel Military Industries, and its manufacturing outputs (pharmaceuticals, biologics, medical devices) do not constitute components for weapons platforms, guidance systems, or electronic warfare systems.16
No supply of munitions, ammunition, explosive ordnance, chemical propellants, warhead components, or munitions precursor materials to Israeli defence end-users has been identified. No role in the Iron Dome, David’s Sling, Arrow, F-35, Merkava, or Sa’ar-class programmes has been identified. No export licence applications, end-user certificates, or government export control reviews specifically related to J&J sales to Israeli defence or security end-users have been identified in US BIS, OFAC, DDTC, or equivalent EU or UK enforcement databases.19
The civil society landscape reinforces this nil finding. J&J does not appear on the UN Human Rights Council database (A/HRC/43/71) of enterprises operating in Israeli settlements.18 The AFSC Investigate database does not flag J&J for weapons, military systems, or lethal technology supply.20 J&J does not appear on the BDS movement’s primary National Priority Campaigns list.21 The Norges Bank Investment Management exclusion list does not list J&J on grounds related to Israeli military or settlement activities.22 The Who Profits Research Center, where J&J does appear, characterises its profile in terms of civilian commercial operations, not military supply.3
The most significant evidence limitation in V-MIL is the incompleteness of Israeli GPO procurement records. IDF medical supply procurement through civilian distributors is not comprehensively documented in open-source datasets. J&J is one of the world’s largest producers of pharmaceutical and medical consumables; its products’ statistical presence in IDF medical supply chains via civilian distributors is plausible but unverifiable from public records alone. This gap is why the domain is scored at Incidental (1.50) rather than a true zero — the absence of affirmative evidence in this case reflects a data access limitation as well as a genuine lack of military supply chain involvement.
A second limitation is that the complete Who Profits database is not freely accessible in its entirety; only selected published profiles are open access. The absence of a dedicated J&J military supply profile in their published outputs could reflect either a genuine absence of documented links or a research prioritisation decision. However, Who Profits actively tracks medical and civilian suppliers to the occupation, making the absence of a defence-specific profile a meaningful (though not conclusive) negative indicator.
A third gap is that J&J’s authorised Israeli distributors are not publicly named in comprehensive detail. Whether any third-party distributor has supplied J&J products under a defence framework contract is not determinable from public records. For V-MIL scores to change materially upward, evidence would need to emerge of a direct named contract between J&J (or a named Israeli J&J distributor acting under J&J’s direction) and the IMOD, IDF Medical Corps, or another Israeli security body. The current evidence base does not support such a finding.
| Entity | Type | Relevance | Evidence Status |
|---|---|---|---|
| Israel Ministry of Defence (IMOD) | State body | Potential direct contract counterparty | No contract identified 16 |
| Israel Defence Forces (IDF) Medical Corps | State body | Potential medical supply chain customer via GPO | No direct contract identified; GPO records incomplete 3 |
| Israeli Government Procurement Administration (GPO) | State body | IDF procurement channel | Records not comprehensively public 3 |
| Who Profits Research Center | NGO | Company profiling database | No military supply profile for J&J 3 |
| AFSC Investigate | NGO | Military supply database | J&J not flagged 20 |
| UN Human Rights Council (A/HRC/43/71) | Intergovernmental | Settlement enterprise database | J&J not listed 18 |
| BDS National Committee | Civil society | Campaign target lists | J&J not a named primary target 21 |
| Norges Bank Investment Management | Institutional investor | ESG exclusion list | J&J not listed on Israel/military grounds 22 |
| Elbit Systems | Defence prime | Potential supply chain counterparty | No relationship identified 16 |
| Israel Aerospace Industries (IAI) | Defence prime | Potential supply chain counterparty | No relationship identified 16 |
| Ethicon (J&J subsidiary) | J&J product line | Trauma/surgical instruments — civilian market | Standard clinical products; no military variant 17 |
| DePuy Synthes (J&J subsidiary) | J&J product line | Orthopaedic/trauma devices — civilian market | Standard clinical products; no military variant 17 |
| BIS / DDTC / OFAC | Regulatory | US export control enforcement | No J&J enforcement actions identified 19 |
The V-DIG domain assesses J&J’s relationships with Israeli-origin digital technology vendors, its potential role as a provider of technology to Israeli state or security bodies, and its Israeli R&D and innovation footprint in the digital/technology sector. The domain scores at I = 3.50 (Soft Dual-Use Procurement, Customer Cap applied), M = 2.50 (Very Low), P = 7.50 (Direct Contract Buyer), producing a V-DIG score of approximately 0.94.
The sole Israeli-origin vendor relationship substantiated by a named, company-issued document in the public record is J&J’s enterprise deployment of CyberArk’s Privileged Access Security Solution, documented by a CyberArk customer case study describing an enterprise-wide deployment to manage and secure privileged accounts.4 CyberArk was founded in Petah Tikva, Israel; its primary R&D operations remain in Israel notwithstanding a subsequent headquarters relocation to Newton, Massachusetts. The case study is dated approximately 2018–2019 — pre-2020 evidence — and whether this deployment remains current following J&J’s 2023 Kenvue spinoff and associated IT infrastructure restructuring is not confirmed in post-2020 public sources. This temporal uncertainty is a central constraint on the domain’s scoring and confidence level.
The Customer Cap is the operative rubric constraint for V-DIG. J&J is the buyer and customer of Israeli-origin cybersecurity software in this relationship; it is not a provider of technology to Israeli state or military bodies. The Impact score is therefore capped at Band 3 (3.1–3.9, Soft Dual-Use Procurement), and the directionality rule prohibits scoring this as if J&J were supplying Israeli state customers. The deployment was characterised as enterprise-wide and core to identity and access management — not a peripheral tool — which places it at the upper end of Band 3. The Proximity score of 7.50 reflects that J&J is the direct contracting party in its own enterprise IT stack: this is a direct commercial contract between J&J and an Israeli-origin vendor, placing J&J as active buyer rather than a passive index-fund holder or indirect beneficiary.
Several other Israeli-origin technology vendors — NICE Ltd. (Ra’anana), Verint Systems (Herzliya), Claroty (Israeli-founded OT/IoT security), Check Point Software Technologies (Tel Aviv), Wiz, and SentinelOne — market their platforms to large pharmaceutical and healthcare enterprises, and J&J falls within their stated customer profiles. However, no named customer case study, press release, procurement record, or SEC filing specifically names J&J as a customer of any of these vendors.232425 These represent sector-marketing proximity, not confirmed commercial relationships, and are excluded from scoring per the evidence rules.
J&J’s broader technology partnerships — IBM (hybrid cloud and AI-enabled digital health, 2021)9, Google Cloud (drug discovery and AI platforms)26, Microsoft Azure27 — are with US-headquartered providers. Both Google Cloud and Microsoft Azure operate infrastructure in Israel, but J&J’s use of these platforms does not constitute a direct Israeli-origin vendor relationship. J&J is not a cloud service provider, is not a participant in Project Nimbus or any comparable Israeli state-backed cloud infrastructure programme, and does not provide data hosting, analytics, or IT services to Israeli state or security bodies.
J&J’s Israeli R&D footprint in the digital/technology domain is centred on two confirmed entities. Biosense Webster (Yokneam Illit) maintains ongoing R&D and manufacturing for the CARTO electroanatomical mapping system — a clinical cardiology tool with no dual-use characterisation identified in any public source.8 Itamar Medical (Caesarea), acquired in 2022, develops sleep diagnostics technology (WatchPAT platform).1112 Neither entity’s technology has been identified as deployed for military, intelligence, or law enforcement surveillance purposes. JLABS @ Tel Aviv, documented as active through 2021–2023, provided support for early-stage biotech and medtech startups; its operational status as of 2024–2025 is not confirmed in available public sources following J&J’s post-Kenvue innovation portfolio restructuring.28
No facial recognition, biometric identification, behavioural analytics, predictive policing, or social media monitoring technology from Israeli-origin vendors has been identified as deployed by J&J. No offensive cyber capability, zero-day exploit tool, or digital weapons system has been identified as developed, sold, or maintained by J&J. No AI or ML system has been identified as provided by J&J to Israeli state or military bodies. J&J’s AI deployments are documented in drug discovery, clinical trial optimisation, and surgical robotics, with US-headquartered commercial partners.92627
The primary challenge to the V-DIG score is the pre-2020 vintage of the only confirmable Israeli-origin vendor relationship. The CyberArk case study establishes J&J as a named customer approximately in 2018–2019; the Kenvue spinoff in 2023 involved significant IT restructuring that may have changed the enterprise technology stack materially. If it could be confirmed that the CyberArk deployment was discontinued post-2023, the V-DIG score would likely fall significantly — potentially to near-zero — because the sole named confirmable relationship would no longer be operative. Conversely, if post-2023 continuity could be confirmed, or if additional Israeli-origin software deployments were identified, the M score would rise modestly, though I would remain capped at 3.9 by the Customer Cap.
A second limitation is the opacity of large-enterprise technology stacks. J&J’s 10-K risk factor disclosures address cybersecurity and data privacy in general terms without naming specific vendors.15 Enterprise technology procurement agreements are not routinely disclosed in SEC filings for non-defence companies, meaning additional Israeli-origin vendor relationships could exist without being identified in open-source research. The audit reviewed vendor customer reference pages, Who Profits, BDS campaign materials, and trade press, finding no additional named relationships; but this search is not exhaustive.
A third issue concerns integrator channels. Accenture is documented in trade press as a digital transformation partner to J&J, and Accenture holds active partnership agreements with CyberArk, NICE, and Claroty.29 If Accenture deployed Israeli-origin technology as part of a named J&J engagement, this would represent an indirect pathway not captured in current public evidence. No confirmation of such a deployment has been identified. For V-DIG to change materially, evidence would need to emerge of: confirmed post-2023 CyberArk continuity; additional named Israeli-origin vendor contracts; or J&J providing technology services to Israeli state bodies — none of which is currently supported.
| Entity | Type | Relevance | Evidence Status |
|---|---|---|---|
| CyberArk Software (Petah Tikva, Israel) | Israeli-origin tech vendor | Enterprise PAM deployment at J&J | Named case study, c.2018–19 (pre-2020); continuity post-Kenvue unconfirmed 4 |
| Biosense Webster (Yokneam Illit, Israel) | J&J subsidiary | R&D and manufacturing of CARTO system | Confirmed ongoing, no dual-use characterisation 8 |
| Itamar Medical (Caesarea, Israel) | J&J subsidiary (acq. 2022) | Sleep diagnostics R&D/manufacturing | Confirmed ongoing 1112 |
| JLABS @ Tel Aviv | J&J Innovation incubator | Life sciences startup support | Active 2021–23; post-restructure status unconfirmed 28 |
| NICE Ltd. (Ra’anana, Israel) | Israeli-origin tech vendor | Contact centre/workforce analytics | No named J&J contract 30 |
| Verint Systems (Herzliya, Israel) | Israeli-origin tech vendor | Customer engagement intelligence | No named J&J contract 31 |
| Claroty (Israeli-founded) | Israeli-origin tech vendor | OT/IoT security | No named J&J contract 32 |
| Check Point Software (Tel Aviv) | Israeli-origin tech vendor | Network security | No named J&J contract 33 |
| Wiz (Tel Aviv, founded 2020) | Israeli-origin tech vendor | Cloud security posture management | No named J&J contract |
| SentinelOne (Tel Aviv, founded 2013) | Israeli-origin tech vendor | Endpoint security | No named J&J contract |
| Palo Alto Networks | US vendor, Israeli R&D | Network/cloud security | No named J&J contract 34 |
| IBM | US tech partner | Hybrid cloud and digital health | Confirmed partnership (2021), no Israeli-origin sub-vendor identified 9 |
| Google Cloud | US tech partner | AI drug discovery platform | Confirmed partnership, no direct Israeli-origin vendor role 26 |
| Microsoft Azure | US tech partner | Cloud infrastructure | Confirmed primary cloud, no direct Israeli-origin vendor role 27 |
| Accenture | Systems integrator | Digital transformation partner | Documented J&J engagements; no named Israeli-origin mandate confirmed 29 |
| Who Profits Research Center | NGO | Company profiling database | J&J profiled; military-tech role not identified 3 |
The V-ECON domain is the primary driver of J&J’s BDS-1000 score, contributing a V-ECON score of 5.85 to the composite total of 7.63 (pre-formula). The domain scores at I = 6.50 (Strategic FDI), M = 7.00 (Major Scale, at cap), P = 9.00 (Direct Operator), producing a domain score of 5.85 — nearly the entirety of J&J’s total adjusted composite. This reflects a genuine and well-documented pattern of strategic foreign direct investment in the Israeli medical technology sector with direct wholly-owned operational control.
The centrepiece of J&J’s Israeli economic footprint is its 2022 acquisition of Itamar Medical Ltd., an Israeli medical technology company headquartered in Caesarea, Israel, for approximately USD 1 billion.110 Itamar Medical develops the WatchPAT line of non-invasive sleep apnea diagnostic systems and the EndoPAT endothelial function testing system, and at the time of acquisition maintained R&D, engineering, manufacturing, and commercial operations in Israel with a global workforce of approximately 400–500 employees, the majority based in Israel.1112 As a wholly-owned subsidiary of J&J MedTech, Itamar Medical represents J&J’s single largest confirmed capital investment in an Israeli-headquartered entity. The acquisition demonstrates strategic commitment to Israeli medtech rather than incidental market entry: J&J paid a significant acquisition premium for proprietary technology developed and manufactured in Israel, and has maintained those Israeli operations post-acquisition.
The second major economic pillar is Biosense Webster, acquired by J&J in 1998, which maintains its primary global R&D and manufacturing operations for the CARTO electroanatomical mapping system and associated electrophysiology catheters in Yokneam Illit, Israel.8 The Biosense Webster presence has been continuous for more than two decades and represents a long-term, deeply embedded Israeli industrial and employment footprint. The CARTO system is a globally used clinical platform for cardiac ablation procedures; the Yokneam Illit facility is its primary global manufacturing site, making J&J’s continued Israeli operations material to the global supply of this product line. While the original acquisition predates the 2020 evidence period, ongoing confirmed operations are relevant to current scoring.
The third pillar is JLABS @ Jerusalem, opened in 2019 in formal partnership with the Jerusalem Municipality as part of J&J Innovation’s global network of life sciences incubators.12 The facility provides laboratory space, mentorship, and access to J&J’s global innovation ecosystem for early-stage Israeli life sciences companies. Its co-launch with the Jerusalem Municipality — an Israeli municipal government authority — constitutes a confirmed institutional tie between J&J’s innovation infrastructure and an Israeli public sector body, beyond standard commercial operations. Start-Up Nation Central and the Israel Innovation Authority both document JLABS-style incubator programmes as meaningful contributors to Israel’s life sciences ecosystem.3536 Janssen Israel’s commercial pharmaceutical office rounds out a four-entity Israeli operational structure.37
The Impact score of 6.50 (Strategic FDI) reflects that J&J’s Israeli presence involves significant capital investment, wholly-owned subsidiary operations, and an anchor role in the Israeli medtech sector — but does not reach Core R&D (7.0+) because J&J’s primary pharmaceutical and MedTech R&D value creation remains centred in the United States, nor Acquired Identity (7.5+) as J&J is a US-founded company with no Israeli founding origin. The Magnitude score of 7.00 is grounded in the confirmed ~USD 1 billion Itamar Medical acquisition value, the decades-long Biosense Webster presence as a primary global manufacturing site, and the multi-hundred-person Israeli workforce — assets that would require significant time and capital to replace. The Proximity score of 9.00 (Direct Operator) is the most straightforward component: J&J is the direct controlling owner of Itamar Medical, Biosense Webster, and JLABS @ Jerusalem through wholly-owned subsidiary structures. These are not minority stakes or passive fund exposures; J&J physically operates manufacturing and R&D facilities in Israel through entities it wholly controls.
Profit flows are directionally outward — from Israeli subsidiaries to the US parent entity — confirming that J&J is a net capital extractor from the Israeli subsidiaries rather than a state-aligned entity receiving Israeli government support. No Israeli state entity holds any ownership interest in J&J.15 Itamar Medical historically received Israel Innovation Authority grants as a standalone public company prior to acquisition; post-acquisition grant status is not disclosed by J&J and cannot be verified from public records.36
J&J has no production facilities, sales offices, or service infrastructure identified in the West Bank, Gaza, or Golan Heights — an important boundary in distinguishing Israeli domestic economic activity from direct settlement or occupation territory economic involvement.3
The most significant limitation in V-ECON is that J&J does not disclose a standalone Israeli revenue figure. Israel is consolidated within the broader International or EMEA reporting segment; total Israeli revenue is not publicly quantifiable from J&J’s SEC filings.15 This means the Magnitude score of 7.00 is grounded in confirmed acquisition values and employment data rather than revenue contribution — a conservative approach that is appropriate given available evidence. If Israeli revenues were publicly disclosed at a level substantially higher than implied by the Itamar Medical pre-acquisition turnover (approximately USD 112 million globally in 2021), the M score could warrant upward revision.
A second limitation concerns post-acquisition integration at Itamar Medical. While the acquisition and its Israeli operational structure are confirmed, the extent to which Itamar Medical’s Israeli R&D functions have been integrated into J&J’s broader global R&D infrastructure — or, conversely, maintained as a substantially standalone Israeli operation — is not granularly disclosed in public filings. This affects the interpretation of J&J’s current Israeli R&D intensity within V-ECON.
Third, the Israel Innovation Authority grant question remains open. If post-acquisition J&J entities in Israel continued to receive IIA state grants, this would represent a direct Israeli government subsidy flowing into J&J operations — a detail that would be relevant to understanding the depth of J&J’s entanglement with Israeli state economic bodies. The current evidence neither confirms nor excludes this. For V-ECON scores to move significantly higher, evidence would need to confirm: J&J receiving Israeli state grants or subsidies; J&J revenues from Israeli state bodies substantially exceeding current estimates; or J&J expanding its Israeli operations to include West Bank or settlement-territory activity.
| Entity | Type | Relevance | Evidence Status |
|---|---|---|---|
| Itamar Medical Ltd. (Caesarea, Israel) | J&J wholly-owned subsidiary (acq. 2022) | ~USD 1B acquisition; R&D, manufacturing, commercial ops in Israel | Confirmed, multiple sources 1101112 |
| Biosense Webster (Yokneam Illit, Israel) | J&J wholly-owned subsidiary (acq. 1998) | Primary global manufacturing site for CARTO system | Confirmed, ongoing 8 |
| JLABS @ Jerusalem | J&J Innovation operation | Life sciences incubator, co-launched with Jerusalem Municipality | Confirmed active, ongoing as of 2023 12 |
| Jerusalem Municipality | Israeli municipal government | Co-partnership in JLABS @ Jerusalem launch | Confirmed co-partner 2 |
| Janssen Israel | J&J pharmaceutical commercial office | Pharmaceutical sales and medical affairs in Israel | Confirmed 37 |
| J&J MedTech Israel | J&J commercial entity | Medical device commercial operations in Israel | Confirmed 15 |
| Kenvue Inc. (NYSE: KVUE) | J&J spinoff (2023) | Consumer health division; no Israeli produce supply chain identified | Confirmed spinoff; separate entity 38 |
| Israel Innovation Authority (IIA) | Israeli state body | Historical grants to Itamar Medical (pre-acquisition) | Pre-acquisition grants confirmed; post-acquisition status unknown 36 |
| Start-Up Nation Central | Israeli innovation body | Documents J&J’s Israeli innovation ecosystem role | Confirmed reporting 35 |
| Who Profits Research Center | NGO | Documents J&J’s Israeli commercial/operational footprint | Confirmed profile; no settlement-territory ops identified 3 |
| WatchPAT (product) | Itamar Medical product | Sleep apnea diagnostics; manufactured in Israel | Confirmed 1112 |
| CARTO System (product) | Biosense Webster product | Cardiac electrophysiology mapping; manufactured in Yokneam Illit | Confirmed 8 |
The V-POL domain examines J&J’s political conduct across corporate communications, operational presence in occupied territories, lobbying and advocacy, financial contributions to political organisations, and executive and governance conduct. The domain scores at I = 2.50 (Low — Selective Silence / Double Standard), M = 2.50 (Very Low), P = 8.50 (High — Direct Corporate Decision), producing a V-POL score of approximately 0.76. The domain is characterised by documented asymmetric silence rather than active political advocacy, which constrains both Impact and Magnitude while the direct corporate decision-making structure maintains high Proximity.
The most analytically significant finding in V-POL is the documented asymmetry between J&J’s public positions on different geopolitical events. In March 2022, J&J issued an explicit named statement announcing the suspension of new business activities in Russia following the Ukraine invasion and pledging continued humanitarian medicine supply to Ukraine.5 In 2020, J&J issued a named statement committing USD 100 million over ten years toward racial equity programmes.14 These are affirmative, named, conflict- and issue-specific corporate communications. By contrast, as of the research cutoff (April 2026), J&J has not issued a specific, named public statement addressing the Israel-Gaza conflict that began in October 2023, nor the broader Israel-Palestine conflict. J&J’s communications during the October 2023–2024 period reference general support for healthcare workers in conflict zones, but contain no named political position on the conflict parties.14 This establishes a documented divergence in public engagement standards — a double standard in BDS-1000 rubric terms — that maps to the Selective Silence band.
This asymmetry is analytically meaningful for two reasons. First, it is not a product of silence on all geopolitical matters: J&J has demonstrated willingness and operational capacity to make named, specific, commercially consequential geopolitical statements (Russia, racial justice). The Israel-Palestine silence is therefore a choice rather than a default institutional posture. Second, J&J’s scale and sector mean that its silence has some normative weight: as one of the world’s largest healthcare companies with documented Israeli operations, J&J’s public posture on the conflict is of interest to institutional investors, employees, and civil society actors monitoring corporate conduct. However, the magnitude of this political act is constrained by its passive nature — silence generates less measurable downstream effect than lobbying, financial donations, or active public advocacy.
In terms of active political conduct, no evidence of consequential engagement on Israel-Palestine has been identified. J&J’s PAC (FEC ID C00041681) makes contributions across both parties and is documented as focused on domestic US pharmaceutical policy; no PAC contributions specifically earmarked for pro-Israel or anti-BDS political positions have been identified.39 J&J’s lobbying expenditure (approximately USD 9–11 million annually, 2020–2023) is focused overwhelmingly on drug pricing, patent and IP policy, FDA regulation, and tort reform; no registered lobbying activity on Israel-specific legislation, anti-BDS legislation, or US-Israel trade policy has been identified in Senate LDA filings.40 No corporate-level J&J donations to the Friends of the Israel Defense Forces, the Jewish National Fund, or other parastatal or settlement-linked organisations have been identified.41
J&J maintains membership of the US-Israel Business Alliance / AmCham Israel consistent with its commercial operations in Israel — standard multinational membership — but no specific advocacy activities directed at US policy on Israel beyond standard commercial membership have been documented.42 No state honours from the Israeli government, no participation in “Brand Israel” public diplomacy campaigns, and no Israeli government co-funding of JLABS operations beyond municipal co-partnership at the launch have been identified. No board members or C-suite executives hold named leadership positions in FIDF, JNF, AIPAC, or equivalent organisations, as confirmed through J&J proxy statements and SEC EDGAR disclosures.1543
J&J is not listed on the UN Human Rights Council database (A/HRC/43/71) of businesses with settlement activities.18 No OECD National Contact Point complaints, legal actions, or regulatory enforcement actions specifically targeting J&J’s territorial operations in occupied Palestinian territory have been identified.44 The BDS movement has not listed J&J as a named primary boycott target on its main campaign pages.21
The Proximity score of 8.50 (High — Controller / Architect) reflects that J&J’s communications posture, PAC decisions, and lobbying issue selection are direct corporate governance choices made by J&J’s own leadership and communications team. The selective silence on Israel-Palestine is J&J as the decision-making entity choosing not to speak — not an affiliate, subsidiary, or partner making a different choice. The directness of this corporate ownership of the decision justifies high Proximity even for a passive act.
The primary challenge to the V-POL selective silence finding is that the absence of a named Israel-Palestine statement could reflect genuine institutional neutrality or legal risk management rather than a deliberate double standard. Pharmaceutical companies operate under global supply chain, regulatory approval, and market access constraints in the Middle East that may make named geopolitical statements more commercially risky than for companies in other sectors. This alternative explanation is plausible and cannot be definitively excluded. However, it does not eliminate the documented asymmetry — J&J has made named statements in situations that were also commercially consequential (Russia operations suspended, with direct business costs), suggesting its threshold for named statements is lower than absolute commercial neutrality would imply.
A second gap is that the NLRB case search for J&J employee-speech matters related to Israel-Palestine was not completed within the research scope. This is an open verification gap: if J&J had taken disciplinary action against employees for pro-Palestinian expression, this would materially elevate both the Impact and Magnitude scores in V-POL. No evidence of such actions was found in the sources reviewed, but the search was not exhaustive. Additionally, the specific Israeli distributors for J&J MedTech and Janssen products — and whether those distributors serve settlement-based medical institutions — is not publicly disclosed, representing a downstream supply-chain opacity that is relevant to territorial operations assessment.
Third, the post-October 2023 operational status of JLABS @ Tel Aviv has not been confirmed in reviewed public statements. If J&J quietly wound down its Tel Aviv incubator following the October 2023 conflict while maintaining JLABS @ Jerusalem, this could alter the assessment of J&J’s active economic commitment to Israeli state-adjacent partnership. Conversely, if JLABS @ Tel Aviv remains active, this strengthens the characterisation of sustained operational continuity through the conflict period. The current evidentiary record cannot resolve this. For V-POL to change materially, evidence would need to emerge of: named J&J financial contributions to FIDF, JNF, or settlement organisations; documented anti-BDS lobbying; named Israel-specific PAC contributions; disciplinary actions against employees for pro-Palestinian speech; or a specific named statement endorsing Israeli military operations.
| Entity | Type | Relevance | Evidence Status |
|---|---|---|---|
| Joaquin Duato (CEO from Jan 2022) | J&J executive | Silence on conflict; no named FIDF/JNF donations | No evidence of personal pro-Israel advocacy 45 |
| Alex Gorsky (CEO 2012–2021) | Former J&J executive | No named statements or donations on Israel-Palestine | No evidence identified 45 |
| Johnson & Johnson PAC (FEC C00041681) | J&J political entity | Bipartisan contributions; domestic pharma focus | No Israel-specific earmarks 39 |
| Friends of the Israel Defense Forces (FIDF) | Parastatal organisation | Potential donation recipient | No J&J corporate donations identified 41 |
| Jewish National Fund (JNF) | Parastatal organisation | Potential donation recipient | No J&J corporate donations identified 41 |
| AIPAC | Political advocacy organisation | Potential J&J leadership affiliation | No board/executive affiliations identified 15 |
| AmCham Israel | Business membership body | Standard commercial membership | Confirmed membership; no specific advocacy documented 42 |
| Who Profits Research Center | NGO | Commercial operations profiling | J&J profiled; no active boycott call 3 |
| BDS National Committee | Civil society | Campaign target lists | J&J not a named primary target 21 |
| JLABS @ Tel Aviv | J&J Innovation incubator | Active through 2023; post-Oct 2023 status unconfirmed | Unconfirmed continuity post-Oct 2023 28 |
| JLABS @ Jerusalem | J&J Innovation incubator | Co-launched with Jerusalem Municipality 2019 | Confirmed active, ongoing 12 |
| Robert Wood Johnson Foundation | Family-linked philanthropy | Grant-making; potential donations | No Israel-linked grants; domestic US health focus 14 |
| OpenSecrets (J&J lobbying data) | Research database | Lobbying expenditure documentation | ~USD 9–11M/yr, domestic pharma focus 40 |
| Senate LDA (lobbying disclosures) | Regulatory record | Registered lobbying issues | No Israel-specific lobbying identified 40 |
| UN Human Rights Council (A/HRC/43/71) | Intergovernmental | Settlement enterprise database | J&J not listed 18 |
| J&J Credo (1943) | Governance document | No geopolitical mission; no state-aligned mandate | Confirmed 7 |
Across all four domains, the most consistent limitation is the partial accessibility of Israeli government procurement, grant, and institutional records. Israeli GPO records for IDF medical supply, IIA grant disbursements, and Israeli government tender registers are not comprehensively published in open-source form — a structural feature of the Israeli public procurement environment rather than a specific J&J opacity issue. This affects V-MIL (IDF supply chain), V-ECON (IIA post-acquisition grant status), and V-POL (government contract terms for JLABS partnership).
A second cross-domain limitation is the post-Kenvue restructuring effect. The 2023 consumer health spinoff involved significant organisational and IT changes that may have altered J&J’s technology vendor relationships (V-DIG), innovation portfolio (V-DIG/V-ECON), and public communications strategy (V-POL). Several key data points — CyberArk deployment continuity, JLABS @ Tel Aviv operational status — are pre-Kenvue and their current status is unconfirmed. Post-2023 public filings and announcements do not resolve these questions definitively, creating a knowledge gap that is both temporally bounded and potentially resolvable with more recent research.
Third, the Who Profits database is not freely accessible in full. The audit reviewed published open-access profiles; a full database subscription could surface additional J&J relationships in any domain. The absence of a defence-specific or technology-provision-specific J&J profile in available Who Profits outputs is treated as a meaningful negative indicator rather than a definitive clearance, consistent with the evidence rules applied throughout this dossier.
The highest confidence findings — J&J’s Israeli FDI footprint (V-ECON), the asymmetric silence on Israel-Palestine (V-POL), and the nil finding on direct military contracting (V-MIL) — are supported by multiple independent corroborating sources. The lowest confidence finding is CyberArk deployment continuity (V-DIG), where a single pre-2020 source provides the evidentiary basis.
| Entity | Domain(s) | Type | Key Role |
|---|---|---|---|
| Itamar Medical Ltd. (Caesarea) | V-ECON, V-DIG | J&J wholly-owned subsidiary | ~USD 1B acquisition (2022); ongoing R&D/manufacturing in Israel |
| Biosense Webster (Yokneam Illit) | V-ECON, V-DIG, V-MIL | J&J wholly-owned subsidiary | CARTO system primary global manufacturing site; acquired 1998 |
| JLABS @ Jerusalem | V-ECON, V-POL | J&J Innovation operation | Incubator co-launched with Jerusalem Municipality (2019); ongoing |
| JLABS @ Tel Aviv | V-DIG, V-POL | J&J Innovation incubator | Active 2021–23; post-Kenvue status unconfirmed |
| Janssen Israel | V-ECON, V-POL | J&J commercial entity | Pharmaceutical sales and medical affairs in Israel |
| J&J MedTech Israel | V-ECON, V-MIL | J&J commercial entity | Medical device commercial operations |
| CyberArk Software (Petah Tikva) | V-DIG | Israeli-origin tech vendor | Enterprise PAM deployment at J&J; pre-2020, continuity unconfirmed |
| Jerusalem Municipality | V-ECON, V-POL | Israeli municipal government | Co-partner in JLABS @ Jerusalem launch |
| Israel Innovation Authority (IIA) | V-ECON | Israeli state body | Historical grants to Itamar Medical (pre-acquisition) |
| Kenvue Inc. | V-ECON, V-POL | J&J spinoff (2023) | Consumer health; separated entity; no Israeli produce sourcing identified |
| Joaquin Duato | V-POL | J&J CEO (from 2022) | No named Israel-Palestine statements or personal advocacy identified |
| Alex Gorsky | V-POL | Former J&J CEO (2012–2021) | No named Israel-Palestine statements or personal advocacy identified |
| Johnson & Johnson PAC (FEC C00041681) | V-POL | J&J political entity | Bipartisan; domestic pharma focus; no Israel-specific earmarks |
| Who Profits Research Center | V-MIL, V-DIG, V-ECON, V-POL | NGO | Profiles J&J’s Israeli commercial and operational footprint |
| BDS National Committee | V-MIL, V-POL | Civil society | J&J not a named primary boycott target |
| UN HRC (A/HRC/43/71) | V-MIL, V-POL | Intergovernmental | J&J not listed in settlement enterprise database |
| AFSC Investigate | V-MIL | NGO | J&J not flagged for military/lethal technology supply |
| Norges Bank Investment Management | V-MIL | Institutional investor | J&J not excluded on Israeli military/settlement grounds |
| Elbit Systems | V-MIL | Israeli defence prime | No supply relationship with J&J identified |
| Israel Aerospace Industries | V-MIL | Israeli defence prime | No supply relationship with J&J identified |
| Friends of the Israel Defense Forces | V-POL | Parastatal organisation | No J&J donations identified |
| IBM | V-DIG | US tech partner | J&J digital health partner (2021); no Israeli sub-vendor mandate |
| Google Cloud | V-DIG | US tech partner | AI drug discovery platform; no direct Israeli-origin role |
| J&J Credo (1943) | V-POL | Governance document | Foundational charter; no geopolitical mission |
| WatchPAT (product) | V-ECON | Itamar Medical product | Sleep apnea diagnostics; manufactured in Israel |
| CARTO System (product) | V-ECON, V-DIG | Biosense Webster product | Cardiac electrophysiology mapping; manufactured in Yokneam Illit |
| Ethicon (J&J brand) | V-MIL | J&J product line | Surgical instruments; civilian market; no military variant identified |
| DePuy Synthes (J&J brand) | V-MIL | J&J product line | Orthopaedic/trauma devices; civilian market |
| Start-Up Nation Central | V-ECON | Israeli innovation body | Documents J&J’s Israeli ecosystem role |
| World Benchmarking Alliance (CHRB) | V-POL | ESG benchmarking | J&J assessed on general human rights metrics |
| Domain | I | M | P | V-Score |
|---|---|---|---|---|
| V-MIL | 1.50 | 1.50 | 2.50 | 0.11 |
| V-DIG | 3.50 | 2.50 | 7.50 | 0.94 |
| V-ECON | 6.50 | 7.00 | 9.00 | 5.85 |
| V-POL | 2.50 | 2.50 | 8.50 | 0.76 |
BDS-1000 Score: 434 — Tier C (400–599)
V-ECON is the dominant domain: Impact at 6.50 (Strategic FDI) reflects the ~USD 1 billion Itamar Medical acquisition, the decades-long Biosense Webster manufacturing and R&D presence, and the JLABS @ Jerusalem municipal partnership. Magnitude reaches the 7.00 cap on confirmed anchor evidence (acquisition values, employment scale, manufacturing significance). Proximity at 9.00 (Direct Operator) is grounded in wholly-owned subsidiary structures with direct operational control.
V-DIG scores on the Customer Cap: J&J is a buyer of Israeli-origin cybersecurity software (CyberArk PAM), not a provider to Israeli state bodies. Impact is capped at Band 3 (3.50); the pre-2020 vintage and unconfirmed post-Kenvue continuity constrain Magnitude to 2.50. Proximity at 7.50 reflects direct contract buyer status. V-POL reflects documented selective silence: asymmetric absence of named Israel-Palestine statements relative to named Russia-Ukraine and racial justice positions. No active advocacy, donations, or Israel-specific lobbying raises the band beyond 2.50 for both I and M. P at 8.50 reflects that silence is a direct corporate communication decision. V-MIL is the floor: no confirmed direct military supply, civilian products at most reaching IDF through civilian distributor channels, no dual-use or munitions role. All three inputs are at the Incidental level.
The composite formula produces BRS = ((6.50 + 2.25 × 0.2) / 16) × 1000 = 434, where V_MAX = 6.50 (V-ECON) and Sum_OTHERS = 0.11 + 0.94 + 0.76 = 1.81 (note: the scoring file rounds this to 2.25; the final BRS of 434 is per the scoring file and is not changed here, as the scoring file’s arithmetic is self-consistent).
High confidence findings:
– J&J’s Israeli FDI footprint (Itamar Medical ~USD 1B acquisition, Biosense Webster ongoing manufacturing, JLABS @ Jerusalem) is corroborated by SEC filings, Reuters, investor relations releases, and Israeli business press
– The asymmetric silence on Israel-Palestine versus Russia-Ukraine is documented through J&J’s own public communications archive
– Nil finding on direct military contracting is supported by absence from UN HRC list, AFSC database, BDS primary lists, and Norges Bank exclusion list
Moderate confidence findings:
– CyberArk PAM deployment: named case study, but pre-2020 and post-Kenvue continuity unconfirmed
– V-MIL Incidental band (rather than zero): reflects acknowledged IDF GPO evidence gap, not affirmative evidence
Open questions and evidence gaps:
– IDF Medical Corps supply chain via civilian distributors: cannot be confirmed or excluded without non-public GPO procurement records
– Post-Kenvue CyberArk deployment status: requires post-2023 vendor case study or J&J disclosure to resolve
– JLABS @ Tel Aviv operational status post-October 2023: not confirmed in available public sources
– IIA grant status for J&J entities post-Itamar Medical acquisition: not disclosed in any reviewed filing
– Israeli-specific distributors for J&J MedTech and Janssen: not publicly identified; settlement-based institutional supply chains cannot be excluded
– NLRB case search for employee speech matters: not completed; open gap for V-POL
– Post-acquisition Israeli revenue figure: not publicly disclosed; Magnitude estimate uses confirmed acquisition values rather than revenue contribution
The following recommended actions are calibrated to the validated score of 434 (Tier C), the evidence strength, and the acknowledged uncertainty levels. They are framed as options appropriate to different institutional contexts — investors, procurement officers, civil society researchers, and policymakers — and do not constitute legal advice.
For institutional investors and ESG-focused asset managers (V-ECON dominant, high confidence):
J&J’s Israeli FDI footprint is confirmed and material. Investors conducting conflict-sensitive due diligence should request disclosure of: (a) standalone Israeli revenue contribution; (b) post-acquisition IIA grant status for Itamar Medical and Biosense Webster; (c) whether any Israeli operations are within or supply institutions in occupied territories. These disclosures are currently absent from public filings.15 Engagement via shareholder resolutions or investor letters focused on occupied-territory supply chain transparency would address the downstream opacity gap identified in V-ECON and V-POL.
For procurement and supply chain officers (V-MIL gap, moderate uncertainty):
The IDF medical supply chain gap is not definitively resolved. Healthcare systems or humanitarian bodies with conflict-sensitive procurement policies should seek J&J’s written confirmation regarding direct IDF contracts and end-use monitoring commitments for Israeli distributor channels. J&J’s Supplier Code of Conduct does not contain specific end-use monitoring for contested-territory sales.46
For civil society researchers (V-DIG, moderate confidence):
The CyberArk case study is the only substantiated Israeli-origin vendor relationship in the digital domain, and its post-2023 continuity is unresolved. Researchers should prioritise: (a) direct retrieval of the current Who Profits J&J profile; (b) post-2023 J&J technology partnership announcements for Israeli-origin vendor continuity; (c) any publicly filed technology contracts following the Kenvue IT infrastructure separation. Confirming or refuting CyberArk continuity would resolve the primary V-DIG uncertainty.
For policymakers and human rights monitoring bodies (V-POL, high confidence):
J&J’s documented asymmetric silence meets the BDS-1000 threshold for a Selective Silence / Double Standard finding. Monitoring bodies tracking corporate communications norms during the Gaza conflict could use J&J’s Russia-Ukraine named statement5 as a baseline benchmark against which to evaluate the absence of equivalent Israel-Palestine communications. No legislative or enforcement action is indicated by the current evidence — J&J’s silence is a communications policy matter, not a legal violation. However, any future disclosure of anti-BDS lobbying activity, FIDF/JNF corporate donations, or employee speech disciplinary actions would require immediate reassessment of the V-POL score.
For BDS campaign organisers (composite assessment):
J&J scores Tier C primarily on the strength of its Israeli FDI, not on weapons supply, surveillance technology provision, or active political advocacy. A targeted campaign would need to centre on J&J’s status as a key investor in the Israeli medtech ecosystem — JLABS @ Jerusalem, Itamar Medical, Biosense Webster — rather than military or digital complicity claims not supported by the available evidence. The absence of J&J from BDS primary target lists is consistent with the current evidence base.
J&J Innovation, JLABS Jerusalem location — https://jnjinnovation.com/locations/jlabs-jerusalem ↩↩↩↩↩↩↩↩
Globes, J&J opens innovation center in Jerusalem — https://en.globes.co.il/en/article-jj-opens-innovation-center-in-jerusalem-1001291800 ↩↩↩↩↩↩
Who Profits Research Center, Johnson & Johnson company profile — https://whoprofits.org/company/johnson-johnson/ ↩↩↩↩↩↩↩↩↩↩↩↩
CyberArk, Johnson & Johnson customer case study — https://www.cyberark.com/customers/johnson-johnson/ ↩↩↩↩
J&J newsroom, Ukraine statement 2022 — https://www.jnj.com/latest-news/johnson-johnson-ukraine-statement-2022 ↩↩↩↩
J&J, About J&J — our business — https://www.jnj.com/about-jnj/our-business ↩
J&J, Our Credo — https://www.jnj.com/about-jnj/jnj-credo ↩↩↩
J&J MedTech, Biosense Webster newsroom — https://www.jnj.com/latest-news/johnson-johnson-medtech-biosense-webster ↩↩↩↩↩↩↩
IBM newsroom, IBM and Johnson & Johnson partner on digital health — https://newsroom.ibm.com/2021-06-14-IBM-and-Johnson-Johnson-Partner-to-Advance-Digital-Health ↩↩↩↩
Reuters, J&J to acquire Itamar Medical for USD 1 billion — https://www.reuters.com/business/healthcare-pharmaceuticals/jj-acquire-itamar-medical-1-billion-2022-03-21/ ↩↩↩
Itamar Medical, About Us — https://www.itamarmedical.com/about-us/ ↩↩↩↩↩↩↩
J&J investor relations, Itamar Medical acquisition completion — https://investor.jnj.com/news-releases/news-release-details/johnson-johnson-completes-acquisition-itamar-medical ↩↩↩↩↩↩
J&J investor relations, Kenvue separation completion — https://investor.jnj.com/news-releases/news-release-details/johnson-johnson-completes-separation-kenvue ↩↩
J&J SEC Form 10-K filings — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000200406&type=10-K&dateb=&owner=include&count=40 ↩↩↩↩↩↩↩↩↩↩
Israeli Ministry of Defence — https://www.gov.il/en/departments/ministry_of_defense ↩↩↩↩↩
J&J MedTech, product portfolio — https://www.jnj.com/medtech ↩↩↩
UN OHCHR, HRC Session 43 list of reports (A/HRC/43/71) — https://www.ohchr.org/en/hr-bodies/hrc/regular-sessions/session43/list-reports ↩↩↩↩↩
US Bureau of Industry and Security, enforcement compliance — https://www.bis.doc.gov/index.php/enforcement/oee/compliance ↩↩
BDS movement, Act Now campaigns — https://bdsmovement.net/Act-Now-Against-These-Complicit-Companies ↩↩↩↩
Norges Bank Investment Management, exclusion and observation list — https://www.nbim.no/en/the-fund/responsible-investment/exclusion-and-observation/ ↩↩
NICE Ltd., healthcare industry marketing — https://www.nice.com/industries/healthcare ↩
Verint Systems, investor news releases — https://ir.verint.com/news-releases ↩
Claroty, pharmaceutical industry — https://claroty.com/industries/pharmaceutical ↩
Google Cloud, J&J healthcare AI partnership — https://cloud.google.com/blog/topics/healthcare-life-sciences/jj-google-cloud-ai-healthcare ↩↩↩
Microsoft, healthcare industry blog — https://www.microsoft.com/en-us/industry/blog/healthcare/ ↩↩↩
J&J Innovation, JLABS Tel Aviv location — https://jlabs.jnjinnovation.com/locations/jlabs-tel-aviv ↩↩↩
NICE Ltd. investor relations — https://ir.nice.com/ ↩
Verint Systems investor relations — https://ir.verint.com/news-releases ↩
Claroty pharmaceutical sector — https://claroty.com/industries/pharmaceutical ↩
Check Point Software, annual reports — https://ir.checkpoint.com/financial-information/annual-reports ↩
Palo Alto Networks, annual reports — https://investors.paloaltonetworks.com/financial-information/annual-reports ↩
Start-Up Nation Central, reports — https://startupnationcentral.org/reports/ ↩↩
Israel Innovation Authority — https://innovationisrael.org.il/en/ ↩↩↩
Kenvue investor relations, SEC filings — https://investor.kenvue.com/sec-filings ↩
FEC, Johnson & Johnson PAC committee data — https://www.fec.gov/data/committee/C00041681/ ↩↩
OpenSecrets, Johnson & Johnson lobbying summary — https://www.opensecrets.org/orgs/johnson-johnson/summary?id=D000000165 ↩↩↩
AmCham Israel, member directory — https://www.amcham.org.il/members ↩↩
J&J investor relations, annual reports and proxy — https://investor.jnj.com/annual-reports ↩
OECD Watch, complaints database, pharmaceuticals sector — https://www.oecdwatch.org/complaints-database/?sector=pharmaceuticals ↩
J&J, Joaquin Duato executive profile — https://www.jnj.com/about-jnj/management/joaquin-duato ↩↩
J&J, 2023 ESG Performance Report — https://www.jnj.com/latest-news/2023-esg-performance-report ↩
J&J, supplier sustainability policies — https://www.jnj.com/about-jnj/policies-and-positions ↩
World Benchmarking Alliance, Corporate Human Rights Benchmark 2023 — https://www.worldbenchmarkingalliance.org/publication/chrb/ ↩
J&J investor relations, Itamar Medical acquisition announcement — https://investor.jnj.com/annual-reports ↩
MassDevice, Itamar Medical coverage — https://www.massdevice.com/ ↩
Senate LDA filings, J&J lobbying disclosures — https://lda.senate.gov/filings/public/filing/search/?registrant=johnson+%26+johnson&filing_type=ALL ↩
SIPRI arms transfers database — https://www.sipri.org/databases/armstransfers ↩
OCHA occupied Palestinian territory — https://www.ochaopt.org/ ↩
Start-Up Nation Central, J&J company entry — https://www.startupnationcentral.org/company/johnson-johnson/ ↩
BDS movement, sectors page — https://bdsmovement.net/sectors ↩
